Related Experiment Video

Updated: Jul 19, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma

Minoru Tomizawa1, Hiromitsu Saisho

  • 1Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8670, Japan. nihminor-cib@umin.ac.jp

World Journal of Gastroenterology
|October 31, 2006
PubMed
Abstract

Insights

Insulin-like growth factor (IGF)-II promotes hepatoblastoma cell growth through the IGF-I receptor and PI3 kinase pathway. This pathway presents a promising target for developing novel molecular therapies for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Hepatoblastoma is a rare pediatric liver cancer.
  • Understanding the molecular mechanisms driving hepatoblastoma growth is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of insulin-like growth factor (IGF)-II as a growth factor in hepatoblastoma.
  • To elucidate the signaling pathway activated by IGF-II in hepatoblastoma cells.
  • To identify potential molecular targets for hepatoblastoma treatment.

Main Methods:

  • Human hepatoblastoma cell lines (Huh-6 and HepG2) were utilized.
  • Insulin-like growth factor (IGF)-II was administered to serum-deprived cells.
  • Western blot analysis assessed IGF-I receptor (IGF-IR) expression.
  • Inhibitors of IGF-IR, PI3-kinase, and MAP kinase were used to probe the signaling pathway.
  • Morphological analysis (hematoxylin-eosin staining) evaluated the impact on cell proliferation and apoptosis.

Main Results:

  • IGF-II significantly increased proliferation in both Huh-6 (2.7-fold) and HepG2 (2.1-fold) cells.
  • IGF-I receptor (IGF-IR) was expressed in both cell lines.
  • Inhibitors of IGF-IR (piclopodophyllin) and PI3-kinase (LY294002, Wortmannin) effectively suppressed cell proliferation.
  • MAP kinase inhibition (PD98059) reduced proliferation in HepG2 cells but not Huh-6 cells.
  • Inhibition of proliferation was associated with increased cellular apoptosis.

Conclusions:

  • IGF-II acts as a potent growth factor for hepatoblastoma cells.
  • The IGF-II signaling pathway in hepatoblastoma involves the IGF-I receptor and PI3 kinase.
  • The IGF-I receptor and PI3 kinase are promising molecular targets for hepatoblastoma therapy.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...